Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

Inclusion Criteria: 1. Men and women, 18-75 years old (both inclusive) at time of screening visit; 2. Subjects with T2DM with inadequate glycemic control defined as central laboratory HbA1c ≥ 7.5 and ≤ 10.5 % at the screening visit; 3. FPG ≤ 15mmol/L at the screening visit; 4. Stable metformin therapy for at least 8 weeks prior to screening at a dose ≥ 1500 mg per day; 5. 19.0\<BMI ≤ 40.0 kg/m2 at the screening visit; Exclusion Criteria: 1. Moderate or severe impairment of renal function \[defined as eGFR\<60mL/min/1.73 m2 (estimated by MDRD); 2. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg; 3. Cardiovascular diseases within 6 months of the screening visit; 4. ALT and/or AST \> 1.5 x ULN and or Total Bilirubin \> 1.2 x ULN; 5. Hemoglobin ≤ 100 g/L; 6. CK (creatine kinase) and CK-MB \> 3 x ULN; 7. Malignancy within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma); 8. Administration of any antihyperglycemic therapy, other than metformin,within 2 months prior to screening;